Inclusion Criteria:

- Diagnosis of unresectable or metastatic melanoma

- Age of 18 years or older at time of diagnosis

- Received at least one prior therapy for unresectable or metastatic melanoma

- Receiving treatment for unresectable or metastatic melanoma at medical practice (e.g.
community-based, office-based, hospital-based, academic setting). Treatment decision
must already have been made by the physician prior to patient's entry in the study

- Ipilimumab-treated patients must be receiving treatment for the indication(s)
approved in their country of residence or where they are receiving treatment

Exclusion Criteria:

- Current or pending participation in a clinical trial examining therapy for the
treatment of any cancer (including unresectable or metastatic melanoma)

- Current use of therapy to treat a primary cancer other than melanoma